Endonovo Therapeutics, Inc.
ENDV · OTC
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.00 | -0.00 | -0.01 |
| FCF Yield | 0.00% | 0.00% | 47.24% | 0.11% |
| EV / EBITDA | -27.74 | -31.70 | -31.25 | -26.52 |
| Quality | ||||
| ROIC | 1.19% | 1.14% | 1.81% | 2.03% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | -0.15 | 0.00 | -0.00 | 0.00 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -80.40% | -57.98% | 4.09% |
| Free Cash Flow Growth | 0.00% | 0.00% | 9,357.66% | -206.73% |
| Safety | ||||
| Net Debt / EBITDA | -27.74 | -30.72 | -30.29 | -31.04 |
| Interest Coverage | -0.80 | -0.75 | -1.16 | -1.25 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | -2,313.10 | -628.99 |